Adam J. Townsend, Chief Commercial Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 220,000 shares at $61.31 ($13.4M) on 2023-12-01, disclosed to the SEC on 2023-12-05.
Scheduled sale ($13.4M) by Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $60.50 | 67,557 | $4.1M | 30.5% |
| 2 | $60.50 | 67,557 | $4.1M | 30.5% |
| 3 | $61.31 | 42,443 | $2.6M | 19.5% |
| 4 | $61.31 | 42,443 | $2.6M | 19.5% |
| Total | $60.81 avg | 220,000 | $13.4M | 100% |
| Filing → |
| APLS | SELL | 2025-01-21 | $132K | — | Filing → |
| APLS | SELL | 2025-01-14 | $154K | — | Filing → |
| APLS | SELL | 2024-02-13 | $156K | — | Filing → |